AIkido Pharma (AIKI) Announces Withdrawal of S-1 Registration Statement

April 22, 2021 9:03 AM EDT

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company has withdrawn its S-1 Registration Statement that was previously filed with the U.S. Securities and Exchange Commission ("SEC"). The Registration Statement has not been declared effective by the SEC, and no securities have been sold in connection with the offering described in the Registration Statement.

Anthony Hayes, CEO of AIkido Pharma, stated, "Recent advancements from our research partners and the anticipated publication of testing data for our technology that is expected in the second quarter of this year, reinforce our optimism around the opportunities for our therapeutic drug platform and the future of the Company. Through a series of recent financing transactions, we believe we are sufficiently capitalized to fund research activities that are currently underway and selectively pursue additional emerging opportunities. Given the current market conditions, we determined it is in the best interest of our shareholders to withdraw the registration statement, while staying the course with our approach to developing commercially viable, effective therapies."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, Equity Offerings, Management Comments

Related Entities

S1